RxDoctor Payments Data

Sherry Yang, MD

Dermatology · Philadelphia, PANPI 1295024057

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 70.9% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $949, more than ten times the $95 reported in 2019. That places this record below the midpoint for dermatology clinicians in PA, where the typical reported total is $1,724.

$2,086in general payments, 2019–2025

Across 44 payments — averaging $47.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$214
  • UCB, Inc.$144
  • Johnson & Johnson$81
  • Regeneron Healthcare Solutions, Inc.$60
  • Galderma Laboratories, L.p.$22
  • plus $86 from 5 others
$122,937in research payments, 2019–2025

Across 22 payments — averaging $5588.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$67K
  • Incyte Corporation$32K
  • Novartis$22K
  • UCB SA$2K

What the payments were for

  • Consulting fees$1,12554%
  • Travel & lodging$251%
  • Food & beverage$93645%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,086 in reported general payments places this provider in the 50th percentile of 626 dermatology providers in Pennsylvania.

See all dermatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$66,485
Medicare patients
423
Services billed
1,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab46$612,689
TremfyaGuselkumab19$253,233
Dupixent PenDupilumab55$207,864
Cosentyx Unoready PenSecukinumab14$152,953
Tacrolimus12$1,023
Clindamycin Phosphate30$754
Clobetasol Propionate15$423
Ketoconazole25$344
Doxycycline Monohydrate12$325
Gabapentin31$231
Triamcinolone Acetonide33$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$81$253,23319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 626 dermatology providers in Pennsylvania.

Other dermatology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →